Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways

Collaborations, Agility Also Key

Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.

There have been lots of expert voices around pandemic-related learnings and regulatory adjustments that have the potential to stick as the world seeks to crawl back to some semblance of normalcy as COVID-19 vaccination gathers pace.

Amgen, Inc. CEO Robert Bradway found himself on tricky terrain on the issue at the recent USA-India Chamber of Commerce annual Biopharma and Healthcare Summit. Biocon, Ltd. chair Kiran Mazumdar-Shaw sought his views around extending emergency use authorizations (EUA) to get drugs faster to market, like for COVID-19 vaccines, and also on whether the controversy around Biogen, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.